Boosting recovery through excitation of arousal and awareness in comatose patients: Dose finding study (BREA2KTHROUGH DOSEFINDER)
Key facts
- Who runs it
- Rigshospitalet
- Where
- Denmark3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 384 people, planned
- Started
- 26 Feb 2025
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional
- Record updated
- 13 August 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Age ≥ 18 years
- Fluent in Danish or English language
- Admission to ICU for severe acute brain injury after trauma, a cerebrovascular accident or anoxic-ischemic/metabolic injury (typically after cardiac arrest) causing coma or another acute DoC (i.e., UWS/VS, MCS), diagnosed by trained investigators
- Unconsciousness is expected by the attending physicians to last for ≥3 days
- Written informed consent for trial participation from both the trial guardian and next-of-kin
Who cannot take part
- Known severe psychotic disorder (e.g., schizophrenia, psychosis after drug abuse, psychotic major depression, current major depression, bipolar disease, but previous history of major depression without psychosis allowed) or a history of a first-degree relative with such a disorder
- Deafness, blindness, or bilateral eye surgery before the onset of brain injury
- Ongoing use of dopamine agonists or antagonists within 6 half-lives of the drug
- Ongoing or previous use of psychoactive or psychotropic substances (including, but not limited to monoamine oxidase inhibitors or medications that are known as uridine diphosphate glucuronosyltransferase enzyme modulators; and ongoing treatments with selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitors medications because of the potential to increase the risk of serotonin syndrome) 2 weeks prior examination or within 6 half-lives of the drug
- Recovery of the ability to follow commands consistently prior to enrolment
- Cardiac valvular disease and pulmonal hypertension (for a theoretical concern that serotonergic agents might aggravate these conditions)
- Ongoing infusion of sedatives/continuous pharmacological sedation (We aim for unsedated patients during neurological examinations, pupillometry and NIRS-EEG, but if patients cannot fully be weaned from sedation, dosages are reduced to the lowest possible level.)
- Lack of Danish or English language proficiency
- Lack of next-of-kin consent
- Residency outside of Denmark
- Expected survival <7 days
- Females of childbearing potential, unless negative HCG test is present
This trial is currently available in Denmark.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To do a dose escalation study to establish the safety of utilizing apomorphine and psilocybin in unresponsive ICU patients with acute brain injury. This is a prospective, open-label, phase 1b, dose escalation study (n=80 patients, i.e., 26 patients with 1 mg psilocybin, 27 patients with 10 mg, and 27 patients with 25 mg psilocybin; all 80 patients receive apomorphine 1-2h after psilocybin administration). The study is authorized and registered as EU-CT 2023-503617-30-02 and is currently recruiting patients as of June 2026. NB: The earlier version EU-CT 2023-503617-30-01 referred to under “Justification for trial category” was subsequently modified after request from the Ethics committee.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 13 August 2026